Table of Contents
Basing Medicaid prices on what other wealthy countries pay could save 47 states and the District of Columbia a combined $8.6 billion, about 35% of net spending on the medications studied, according to research published July 15 in JAMA examining potential Medicaid drug pricing savings.
How Researchers Modeled Medicaid Drug Pricing Savings
The analysis, led by Thomas Hwang, MD, of Boston-based Brigham and Women’s Hospital, modeled the CMS Generating Cost Reductions for US Medicaid, or GENEROUS, model. Under most-favored-nation pricing, manufacturers give participating state Medicaid programs added rebates whenever Medicaid’s net price surpasses the price paid abroad.
Background on the GENEROUS Pilot Program
CMS announced the voluntary model in November 2025 and launched it in January. It will run five years, and 17 pharmaceutical companies had agreed to participate, as of May, in exchange for protection from import tariffs on their products, a structure that gives manufacturers a concrete incentive to opt into the program.
The Scope of Medications Studied for Medicaid Drug Pricing Savings
Researchers examined 82 brand-name medications with at least $100 million in annual Medicaid spending and no generic or biosimilar competition, together representing $43 billion in gross Medicaid spending and $25.2 billion net after existing rebates. Focusing on high-spend, no-competition products allowed researchers to isolate where most-favored-nation pricing could have the largest financial impact.
How Much Cheaper These Products Are Abroad
More than 90% cost less in the reference countries than their net Medicaid prices, a striking finding that underscores just how large the pricing gap between the U.S. and comparable wealthy nations has become for these specific therapies.
What These Medicaid Drug Pricing Savings Would Mean in Practice
The projected savings would equal raising the statutory minimum Medicaid rebate from 23.1% to 49.2%, a substantial policy shift if achieved through the current rebate framework rather than the most-favored-nation mechanism modeled in this study.
Savings Concentrated Among Already-Participating Companies
The savings are concentrated among manufacturers that have already signed on: participating companies accounted for 87.8% of Medicaid spending and 93.9% of estimated savings, the authors said. This concentration suggests that even with just 17 companies currently enrolled, the GENEROUS model could already be capturing the vast majority of available Medicaid drug pricing savings without needing full industry-wide participation.
Risks and Cautions Around Medicaid Drug Pricing Savings
The authors cautioned that most-favored-nation schemes are vulnerable to gaming, as manufacturers can delay launches abroad, create country-specific formulations, or obscure true prices. These strategies could allow companies to technically comply with the pricing model while limiting the actual savings realized by state Medicaid programs.
Watching for Spillover Effects
Researchers urged policymakers to watch for spillover effects on pricing in other countries and for other payers, a concern that reflects how most-favored-nation policies in one market can create ripple effects across global pharmaceutical pricing structures more broadly.
What This Means for the Future of Medicaid Drug Pricing Savings
With the GENEROUS model still in its early stages and running through a five-year pilot period, this JAMA analysis offers an early data-driven estimate of just how significant Medicaid drug pricing savings could become if adoption expands beyond the current 17 participating companies. Given the scale of savings already concentrated among current participants, policymakers may see this research as evidence supporting broader manufacturer participation, while also needing to build in safeguards against the gaming risks researchers identified.
For more healthcare industry updates, insights and news, visit DistilINFO. Click here to subscribe to stay informed.
